Back

Reduction of human Alzheimer's disease risk and reversal of mouse model cognitive deficit with nucleoside analog use

Magagnoli, J.; Yerramothu, P.; Ambati, K.; Cummings, T.; Nguyen, J.; Thomas, C.; Wang, S.-b.; Cheng, K.; Juraev, M.; Dholkawala, R.; Nagasaka, A.; Ambati, M.; Nagasaka, Y.; Ban, A.; Ambati, V.; Sutton, S. S.; Gelfand, B.; Ambati, J.

2023-03-21 neurology
10.1101/2023.03.17.23287375 medRxiv
Show abstract

Innate immune signaling through the NLRP3 inflammasome has been implicated in the pathogenesis of Alzheimers disease (AD), the most prevalent form of dementia. We previously demonstrated that nucleoside reverse transcriptase inhibitors (NRTIs), drugs approved to treat HIV and hepatitis B infections, also inhibit inflammasome activation. Here we report that in humans, NRTI exposure was associated with a significantly lower incidence of AD in two of the largest health insurance databases in the United States. Treatment of aged 5xFAD mice (a mouse model of amyloid-{beta} deposition that expresses five mutations found in familial AD) with Kamuvudine-9 (K-9), an NRTI-derivative with enhanced safety profile, reduced A{beta} deposition and reversed their cognitive deficit by improving their spatial memory and learning performance to that of young wild-type mice. These findings support the concept that inflammasome inhibition could benefit AD and provide a rationale for prospective clinical testing of NRTIs or K-9 in AD.

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

50% of probability mass above